The global immunoglobulin market size was estimated to be USD 16.47 billion in 2023 and is expected to reach at USD 44.28 billion by 2034 with a CAGR of 9.41% during the forecast period 2024-2034. Surge in prevalence immunodeficiency disease, growing adoption of immunoglobulin, rising research & development activities, increasing need for effective treatment, surge in advancements in treatment options, growing focus on the development of innovative drugs, rising number of launches by leading market players, and increasing approval from regulatory authorities are some of the key factors boosting the market growth.
Increasing approval from regulatory authorities is predicted to fuel the market growth during the forecast period. The growing incidence of autoimmune disorders like Guillain-Barré Syndrome and the recognition of the clinical effectiveness of immunoglobulin in treating these conditions have contributed to a higher demand for innovative products. Consequently, the increasing prevalence of these significant disorders, coupled with advancements in treatment options involving this product, is driving up demand and the adoption rate of immunoglobulin, thereby promoting growth in the immunoglobulin market. For instance, in January 2022, Octapharma's human immunoglobulin for subcutaneous administration, known as cutaquig, has received an extended indication from the European Union. This expansion now includes patients with various forms of secondary immunodeficiency who require immunoglobulin replacement therapy.
By product, IgG was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to its wide application of IgG in treating several disorders, surge in research & development activities, and increasing approval by the regulatory authorities for the expansion of manufacturing process for immunoglobulins. For instance, in March 2023, Kamada Ltd. has received authorization from the U.S. FDA to produce Cytomegalovirus Immune Globulin Intravenous [Human] (CMV-IGIV) at its facility in Israel. This FDA approval signifies the successful conclusion of the technology transfer process for CYTOGAM from CSL Behring. Kamada stands to gain from the addition of four FDA-approved IgGs to its product portfolio, and they anticipate further product development in the coming years. The company is preparing to commence commercial production of CYTOGAM at its Israeli plant soon, which will enhance the facility's efficiency and utilization. Additionally, IgA is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on the development of innovative drugs and growing approvals by regulatory bodies.
By route of administration, intravenous was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to surge in number of strategic initiatives regarding intravenous immunoglobulin, growing number of research & development activities, increasing drug approval from the regulatory authorities. For instance, in January 2022, Argenx SE, a worldwide immunology company dedicated to enhancing the well-being of individuals afflicted by severe autoimmune conditions, has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for the intravenous infusion of VYVGART (efgartigimod alfa) to treat adult patients suffering from generalized myasthenia gravis (gMG) when steroids or non-steroidal immunosuppressive therapies (ISTs) have not yielded an adequate response. Additionally, subcutaneous is predicted to grow at fastest CAGR during the forecast period owing to the cost effectiveness, relatively low risk associated with systemic illness, & self-administration capabilities, rising approvals of novel products by regulatory bodies.
By application, primary immunodeficiency diseases was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to the rising prevalence of primary immunodeficiency diseases, increased use of this plasma product to treat certain conditions. Additionally, chronic Inflammatory demyelinating polyneuropathy (CIDP) is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities and growing focus on introduction of advanced drugs for the treatment of CIDP by key market players. For instance, in March 2023, A distribution partnership has been established between Advanced Infusion Care (AIC) and Kendrion S.p.A. This collaboration is centered on the distribution of GAMMAKED, a treatment employed for addressing immune thrombocytopenia (ITP) in both adults and children, along with chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
By end-user, hospitals was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to the rising healthcare infrastructure, healthcare personnel monitoring patients around-the-clock, increase in hospital settings & inpatient admissions, surge in prevalence of immunodeficiency disorders, and growing regulatory approvals of novel products. For instance, in March 2022, Grifols has gained approval from various health authorities in European Union member states, as well as from the United Kingdom, for XEMBIFY. This novel 20% subcutaneous immunoglobulin (SCIG) has been authorized for the treatment of primary and specific secondary immunodeficiencies. Additionally, homecare is predicted to grow at fastest CAGR during the forecast period owing to the growing inclination among the general public for in-home care settings and increased efforts by the major companies to introduce in-home care equipment.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing level of consciousness for the products involved in the treatment of immunodeficiency disorders, rising healthcare expenditure, growing inclination of clinicians toward immunodeficiency therapies, and surge in collaborations within market players. For instance, in March 2022, Sanofi has entered into an exclusive global collaboration agreement with IGM Biosciences to jointly create, develop, manufacture, and market a total of six antibody agonists belonging to the immunoglobulin (IgM) class. This collaboration will focus on three antibody agonists targeting immunology and inflammation-related targets and three targeting oncology-related targets. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing government efforts to offer expensive IG treatments at a reasonable price, growing healthcare expenditure, surge in number of patients suffering from immunodeficiencies, rising reimbursement policies, and increasing regulatory approvals. For instance, in January 2022, The intravenous infusion of VYVGART (efgartigimod alfa) has been approved by the Ministry of Health, Labour, and Welfare (MHLW) of Japan, according to an announcement from Argenx SE. This approval is for the treatment of adults with generalized myasthenia gravis (gMG) who do not experience an adequate response to steroids or non-steroidal immunosuppressive therapies (ISTs).
Increasing approval from regulatory authorities is predicted to fuel the market growth during the forecast period. The growing incidence of autoimmune disorders like Guillain-Barré Syndrome and the recognition of the clinical effectiveness of immunoglobulin in treating these conditions have contributed to a higher demand for innovative products. Consequently, the increasing prevalence of these significant disorders, coupled with advancements in treatment options involving this product, is driving up demand and the adoption rate of immunoglobulin, thereby promoting growth in the immunoglobulin market. For instance, in January 2022, Octapharma's human immunoglobulin for subcutaneous administration, known as cutaquig, has received an extended indication from the European Union. This expansion now includes patients with various forms of secondary immunodeficiency who require immunoglobulin replacement therapy.
By product, IgG was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to its wide application of IgG in treating several disorders, surge in research & development activities, and increasing approval by the regulatory authorities for the expansion of manufacturing process for immunoglobulins. For instance, in March 2023, Kamada Ltd. has received authorization from the U.S. FDA to produce Cytomegalovirus Immune Globulin Intravenous [Human] (CMV-IGIV) at its facility in Israel. This FDA approval signifies the successful conclusion of the technology transfer process for CYTOGAM from CSL Behring. Kamada stands to gain from the addition of four FDA-approved IgGs to its product portfolio, and they anticipate further product development in the coming years. The company is preparing to commence commercial production of CYTOGAM at its Israeli plant soon, which will enhance the facility's efficiency and utilization. Additionally, IgA is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on the development of innovative drugs and growing approvals by regulatory bodies.
By route of administration, intravenous was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to surge in number of strategic initiatives regarding intravenous immunoglobulin, growing number of research & development activities, increasing drug approval from the regulatory authorities. For instance, in January 2022, Argenx SE, a worldwide immunology company dedicated to enhancing the well-being of individuals afflicted by severe autoimmune conditions, has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for the intravenous infusion of VYVGART (efgartigimod alfa) to treat adult patients suffering from generalized myasthenia gravis (gMG) when steroids or non-steroidal immunosuppressive therapies (ISTs) have not yielded an adequate response. Additionally, subcutaneous is predicted to grow at fastest CAGR during the forecast period owing to the cost effectiveness, relatively low risk associated with systemic illness, & self-administration capabilities, rising approvals of novel products by regulatory bodies.
By application, primary immunodeficiency diseases was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to the rising prevalence of primary immunodeficiency diseases, increased use of this plasma product to treat certain conditions. Additionally, chronic Inflammatory demyelinating polyneuropathy (CIDP) is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities and growing focus on introduction of advanced drugs for the treatment of CIDP by key market players. For instance, in March 2023, A distribution partnership has been established between Advanced Infusion Care (AIC) and Kendrion S.p.A. This collaboration is centered on the distribution of GAMMAKED, a treatment employed for addressing immune thrombocytopenia (ITP) in both adults and children, along with chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
By end-user, hospitals was the highest revenue-grossing segment in the global immunoglobulin market in 2023 owing to the rising healthcare infrastructure, healthcare personnel monitoring patients around-the-clock, increase in hospital settings & inpatient admissions, surge in prevalence of immunodeficiency disorders, and growing regulatory approvals of novel products. For instance, in March 2022, Grifols has gained approval from various health authorities in European Union member states, as well as from the United Kingdom, for XEMBIFY. This novel 20% subcutaneous immunoglobulin (SCIG) has been authorized for the treatment of primary and specific secondary immunodeficiencies. Additionally, homecare is predicted to grow at fastest CAGR during the forecast period owing to the growing inclination among the general public for in-home care settings and increased efforts by the major companies to introduce in-home care equipment.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing level of consciousness for the products involved in the treatment of immunodeficiency disorders, rising healthcare expenditure, growing inclination of clinicians toward immunodeficiency therapies, and surge in collaborations within market players. For instance, in March 2022, Sanofi has entered into an exclusive global collaboration agreement with IGM Biosciences to jointly create, develop, manufacture, and market a total of six antibody agonists belonging to the immunoglobulin (IgM) class. This collaboration will focus on three antibody agonists targeting immunology and inflammation-related targets and three targeting oncology-related targets. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing government efforts to offer expensive IG treatments at a reasonable price, growing healthcare expenditure, surge in number of patients suffering from immunodeficiencies, rising reimbursement policies, and increasing regulatory approvals. For instance, in January 2022, The intravenous infusion of VYVGART (efgartigimod alfa) has been approved by the Ministry of Health, Labour, and Welfare (MHLW) of Japan, according to an announcement from Argenx SE. This approval is for the treatment of adults with generalized myasthenia gravis (gMG) who do not experience an adequate response to steroids or non-steroidal immunosuppressive therapies (ISTs).
Segmentation: Immunoglobulin Market Report 2022 - 2033
Immunoglobulin Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- IgM
- IgG
- IgE
- IgA
- IgD
Immunoglobulin Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Subcutaneous
- Intravenous
Immunoglobulin Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Secondary Immunodeficiency Disease
- Hypogammaglobulinemia
- Guillain Barre Syndrome
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Immunodeficiency Disease
- Multifocal Motor Neuropathy
- Myasthenia Gravis
- Immune Thrombocytopenic Purpura
- Other
Immunoglobulin Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Homecare
- Clinics
- Hospitals
Immunoglobulin Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Immunoglobulin Market: Product Estimates & Trend Analysis
8. Immunoglobulin Market: Route of Administration Estimates & Trend Analysis
9. Immunoglobulin Market: Application Estimates & Trend Analysis
10. Immunoglobulin Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Immunoglobulin Market
13. Europe Global Immunoglobulin Market
14. Asia Pacific Global Immunoglobulin Market
15. Latin America Global Immunoglobulin Market
16. MEA Global Immunoglobulin Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Kendrion Biopharma Inc.
- ADMA Biologics Inc.
- China Biologic Products Inc.
- Grifols S.A.
- Csl Limited
- Biotest Ag
- Octapharma Ag
- Shire Plc. (Baxalta)
- Baxter International Inc.
- Bayer Ag
- Advanced Infusion Care (AIC)
- Lfb Sa (Lfb Biotechnologies Sas)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.47 Billion |
| Forecasted Market Value ( USD | $ 44.28 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
